A recent peer-reviewed publication in Stereotactic and Functional Neurosurgery details the initial clinical experience with NeuroOne Medical Technologies Corporation's OneRF Ablation System, the first FDA-cleared system capable of using the same sEEG electrode for both diagnostic and therapeutic applications in neurological disorders. The case series, accessible via PubMed at https://pubmed.ncbi.nlm.nih.gov/41785222/, reports on four consecutive patients with drug-resistant epilepsy treated at a leading U.S. epilepsy center, highlighting the technology's safety and clinical potential.
The importance of this development lies in addressing a significant unmet need for patients with drug-resistant epilepsy who have limited treatment options. The authors note this represents a significant advancement for patients undergoing sEEG for invasive evaluation, potentially transforming how neurological disorders are managed. The system allows radiofrequency ablation without removing or repositioning already implanted sEEG electrodes, enabling treatment delivery directly through implanted electrodes while monitoring temperature in real time for precise, controlled lesions that minimize risk to surrounding brain structures.
Clinically, the procedure proved safe with no adverse events reported, and all four patients experienced reductions in seizure burden following treatment. The technology's integration into existing stereotactic neurosurgical workflows allows treatment either in the operating room or at the patient's bedside in the epilepsy monitoring unit, increasing accessibility and potentially reducing hospital resource utilization. Additionally, the procedure provided information that helped guide subsequent surgical decision-making, highlighting its dual value as both diagnostic and prognostic tool.
For the medical industry, NeuroOne's technology represents a convergence of diagnostic and therapeutic capabilities within a single platform. The company now boasts a full line of thin film electrode technology to address patients requiring diagnostic brain mapping procedures as well as RF ablation using the same sEEG electrode. NeuroOne estimates the current combined sEEG and brain ablation market to be at least $200 million worldwide and growing, with potential for multifold growth based on large addressable patient populations with unmet clinical needs.
The broader implications extend to healthcare systems and patients worldwide who struggle with neurological disorders. By offering combination diagnostic and therapeutic functions, this technology could potentially reduce the number of hospitalizations and surgical procedures while lowering costs and improving patient outcomes. As the first device with a therapeutic indication among NeuroOne's FDA-cleared products, the OneRF Ablation System marks a pivotal step toward more integrated neurological care solutions that address both diagnosis and treatment within unified clinical workflows.
